Brand Information

Updated On: 27-02-2024

Home

About Us

FAQs

Feedback

Disclaimer

Site Map

Home > Search > > DROXYL

DROXYL

Brand:
DROXYL

Manufacturer:
TORRENT

Manufacturer Details
TORRENT

Compositions:
Cefadroxyl monohydr 125mg/250mg/500mg tablets/ 250mg/5ml oral suspension,

Strength	Rate	Packing Style
125mg	13.20	10s tablets
250mg	31.20	10s tablets
500mg	45.15	10s tablets
250mg/5ml	27.00	30ml oral suspn

List of Related Indications:

ENT infection
Osteomyelitis
Respiratory tract infection
Skin & soft tissue infection
Urinary tract infections- UTI

List Of Drugs:

Cefadroxil - Cephalosporins @ - First generation- (FDC-List) (Feb 1989)

Indication Type Description:

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Other Information

Patient Information

Pharmacology/ Pharmacokinetics

Interaction with Food

Pregnancy and lactation

Drug Interaction:

Drugs covered:

1st generation 2nd generation 3rd generation .

Cephalexin Cefaclor Cefixime Cefadroxil Cefamandole Cefoperazone Cephadrine Cefotoxitin Cefotaxime Cephalothin Cefuroxime Ceftizoxime Cephapirin Cefonicid Ceftriaxone Cefazolin Cefmetazole Ceftazidime Cefotetan Ceftibuten Cefprozil Cefepime Cefpodoxime Loracarbef

Refer Cephalosporins

Concurrent use with frusemide increases risk of nephrotoxicity.

Potentiates nephrotoxicity of aminoglycosides.

Prothrombin time prolonged, caution necessary with anticogulants.

Probenecid prolongs half-life.

Indication:

U.S.FDA APPROVED DRUGS FROM 01-01-08 TO 31-12-08

Drug name Indication Date of Approval

167. Cefadroxyl (as monohydrate) 125mg 24-07-08

+ Clavulanic acid (as potassium) 31.25 per 5ml

syrup

(Addl.stgth)

same as approved

U.S FDA APPROVED DRUGS DURING 2006

121. Cefadroxil 500mg + 30-08-2006

Clavulanic acid 125mg tablet Antibiotic

122. Cefadroxil 250mg + 30-08-2006

Clavulanic acid 62.5mg dispersible tablet Antibiotic

123. Cefadroxil 250mg + 30-08-2006

Clavulanic acid 62.5mg per 5ml syrup Antibiotic

Drugs covered:

1st generation 2nd generation 3rd generation .

Refer Cephalosporins

A First generation drug

Approved by (DCI) Drug Controller GENERAL - India For Marketing

(Ref- IDMA Publication)

Name of Drug Indication Date of Approval

1.Cefadroxl Antibiotic February 1989

2.Cefadroxyl 250mg +Clavulanic acid 30-08-2006

62-5mg per 5ml syrup

Antibiotic

3.Cefadroxil 250mg + Clavulanic acid 30-08-2006

62.5mg dispersible tablet

Antibiotic

4. Cefadroxyl 500mg + Clavulanic acid 30-08-2006

125mg tablet

Antibiotic

5. Cefadroxyl (as monohydrate ) 125mg 25-07-2008

+ Clavulanic acid (as potassium)

31.25 5ml syrup

Addl.strength

Same as approved

FIXED DOSE COMBINATIONS APPROVED BY DCG(I)

FROM JANUARY 1961 TILL NOVEMBER 2014

Name of Drug Indication Date of Approval

1.Cefadroxyl 250mg+ 30-08-2006

Clavulanic acid 62.5mg dispersible tablet

For the treatment of adult patients with infectionscaused by susceptible

microorganisms caused by S.Auteus .viz. Urinary tract infection. Lower

Respiratory Tract Infections and gonococccal urethritis

2. Cefadroxil 250mg+ 30-08-2006

Clavulanic acid 62.5mg per 5ml syrup

For the treatment of adult patients with infectionscaused by susceptible

microorganisms caused by S.Auteus .viz. Urinary tract infection. Lower

Respiratory Tract Infections and gonococccal urethritis

3.Cefadroxil 500mg + 30-08-2006

Clavulanic acid 125mg film coated tablets

For the treatment of adult patients with infectionscaused by susceptible

microorganisms caused by S.Auteus .viz. Urinary tract infection. Lower

Respiratory Tract Infections and gonococccal urethritis

4.Cefadroxyl as monohydrate 125mg + 25-07-2008

Clavulanic acid (as Potassium) 31.25per 5ml syrup

Addl.stgth

For the treatment of adult patients with infectionscaused by susceptible

microorganisms caused by S.Auteus .viz. Urinary tract infection. Lower

Respiratory Tract Infections and gonococccal urethritis

Adverse Reaction:

Anaphylactic reactions.

Nausea,vomiting, diarrhoea, abdominal discomfort.

Allergic reactions such as skin rash, urticaria, eosinophilla, angioedema. Rise in liver enzyme values.

Superinfection with resistent organisms(esp candida) Possibility of pseudomembranous colitis.

False urinary reaction of urinary glucose, development of positive coombs test.

Interferes with cross matching of blood.

False positive precipitation test with proteins.

Contra-Indications:

Known allergy to cephalosporins.

Special precautions:

If hypersen reactions occur, discontinue drug & treat suitably.

Prolonged use may cause over-growth of non-suseptible organisms.

If superinfection occurs take appropiate measures.

Caution in patients with history of GI disease especially colitis.

Dosages/ Overdosage Etc:

A first generaration drug.

Indications:

Urinary tract infection, skin & skin structure infections, pharyngitis, tonsilitis.

Food interaction: Can be given without regards to meals.

Dosage:

1 or 2g/day in single or divided doses.

Children: 30mg/kg/day in divided doses every 12 hours..

Other Information:

For Availability/supplies

Contact -

1.Indian Drug Manufacturers Association (IDMA)

Phone- 022- 24944624/ 24974308

Fax- 022- 24950723

Email- idma@vsnl.com

Website: www.idma-assn.org

2.Bulk Drug Manufacturers Association (India)(BDMA)

Phone - 040-23703910/ 23706718

Fax- 040-23704804

Email- info@bdmai.org

Website: www.info@bdmai.org

Patient Information:

Refer cephalosporins

Pharmacology/ Pharmacokinetics:

Refer cephalosporins

Interaction with Food:

Can be given without regards to meals.

Pregnancy and lactation:

Refer cephalosporins

Search

Look In

Keyword

Mode

	Starts With		Contains

Quick Links

Home
About Us
FAQs
Site Map
Disclaimer

Free Mobile App

About Us

FAQs

Feedback

Disclaimer: Every effort has been made to ensure that the information provided in this Database is authentic and accurate. Commissions or omissions in the database, if any, are purely inadvertent and the site owner shall not accept any liability whatsoever for any adverse consequences of any nature arising to any individual or third party, as a result of usage of this information.